Nature

The MUC1 mucin specifically inhibits activation of the NLRP3 inflammasome

MUC1 is a cell membrane-associated mucin, expressed ubiquitously on the mucosal epithelia as well as by immune cells, that limits the inflammatory response to multiple pathogens. We have recently ...
Nature

MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor

MUC1 is a membrane-bound glycoprotein that belongs to the mucin family. It is involved in cell adhesion and intracellular signaling. Aberrant expression of MUC1 has been observed in different ...
Business Wire

Minerva Biotechnologies - Overcoming the Solid Tumor Barrier: MUC1*-Targeted CAR T bearing 1XX mutations overcomes exhaustion and enables killing of low antigen expressing ...

WALTHAM, Mass.--(BUSINESS WIRE)--Minerva Biotechnologies published “Effective CAR T cell targeting of a MUC1 cleavage product” in the Journal for ImmunoTherapy of ...
ascopubs.org

Ablating MUC1+ tumor and cancer stem cells by targeting the MUC1 oncoprotein with configurational-specific monoclonal antibodies and peptides.

Nonmyeloablative conditioning with mesenchymal stem cell transplantation for type 1 diabetis mellitus. Background: MUC1, a glycoprotein overexpressed by breast, intestinal, pancreatic, and gastric ...
ascopubs.org

New MUC1 Serum Immunoassay Differentiates Pancreatic Cancer From Pancreatitis

Multipopulation Analysis of Polymorphisms in Five Mononucleotide Repeats Used to Determine the Microsatellite Instability Status of Human Tumors At a cutoff of 10.2 units/mL, 41 (77%) of 53 pancreatic ...
Business Wire

Minerva Biotechnologies Gets FDA Approval of IND for a MUC1*-CAR-1XX with Increased Persistence and Ability to Kill Low Antigen Expressing Cells for Treatment of Solid Tumor ...

WALTHAM, Mass.--(BUSINESS WIRE)--Minerva Biotechnologies, a private company developing 1 st-in-human therapies for the treatment of solid tumor cancers, announced today that the FDA has approved their ...